Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
This study has been completed.
Cancer and Leukemia Group B
Information provided by:
National Cancer Institute (NCI)
First received: August 3, 2000
Last updated: December 26, 2009
Last verified: October 2003
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006 Aug;47(8):1511-7.
Smith SM, Johnson JL, Niedzwiecki D, et al.: Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: results of CALGB 59906, a phase II study of doxorubicin and topotecan. [Abstract] Blood 104 (11): A-2500, 2004.